Firm
Benjamin Grzimek, partner at Casalonga’s new Düsseldorf office, believes the firm is well-placed to challenge German UPC dominance
A lot of the reporting around the Anthropic settlement misses something critical: it isn’t that relevant to AI training, argues Rebecca Newman at Addleshaw Goddard
Justin Hill and Marie Jansson Heeks, part of an 18-strong team to have joined Crowell & Moring, explain why IP client advice must go beyond only being called upon for patent disclosure
To mark the EUIPO having processed five million EUTM and REUD applications, Managing IP speaks to the most prolific representatives to uncover how they stay at the top of their game
Sponsored
Sponsored
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Parth Bajaj of RNA, Technology and IP Attorneys consider the potential impact of two US cases on Indian jurisprudence and what constitutes fair use of copyrighted material in training AI models
-
Sponsored by Tilleke & GibbinsThe measures represent a ‘strategic leap’ for Vietnam’s intellectual property landscape, say Thuy Thi Ngoc Huynh and Yen Thi Hai Pham of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law analyses a ruling that clarifies the scope of patent infringement, territoriality limits, and research exemptions in a cross-border dispute over Pfizer’s pneumococcal vaccine
-
Sponsored by Saint Island International Patent & Law OfficesJulia Y M Hung of Saint Island International Patent & Law Offices explains the implications of a ruling confirming that assignees inherit both rights and defects, even in cases involving an unsettled distributorship dispute
-
Sponsored by Spoor & FisherDavid Cochrane of Spoor & Fisher South Africa explains the key updates under the act, which strengthens breeder protections while supporting vulnerable farmers and aligning with international norms
-
Sponsored by Maiwald Intellectual PropertyKerstin Wolff of Maiwald Intellectual Property examines the EU’s winding path towards the regulation of new genomic techniques, with a proposed patent ban remaining a key source of contention